肠道微生物与性激素相关疾病研究进展

doi:10.13560/j.cnki.biotech.bull.1985.2019-0955

摘要/Abstract

摘要： 数以万亿计的微生物生活在人类肠道中,形成了一个复杂的微生态群落。肠道微生物可为宿主提供营养和能量,并与人类疾病的发生发展密切相关。随着研究的不断深入,越来越多的证据表明肠道微生物的改变可引起性激素水平变化,进而导致一系列相关的疾病发生。本文就肠道微生物与多囊卵巢综合征、乳腺癌、卵巢癌等性激素相关疾病之间的关系进行阐述,旨在为人类疾病诊疗提供新思路。

关键词: 肠道微生物, 性激素, 多囊卵巢综合征, 乳腺癌, 卵巢癌

Abstract: Trillions of microbes inhabit the human intestine,forming a complex microecological community. It is clear that intestinal microorganisms provide nutrients and energy to the host and are involved in the occurrence and development of human diseases. With the deepening of relevant researches,growingly evidences indicate that changes in intestinal microorganisms cause variations in sex hormone levels,thus leading to a series of related diseases. In this review,we discuss the relationships between intestinal microorganisms and sex hormone-related diseases such as polycystic ovary syndrome,breast cancer and ovarian cancer,etc.,aiming to provide new ideas for the diagnosis and treatment of human diseases.

Key words: intestinal microorganisms, sex hormones, polycystic ovary syndrome, breast cancer, ovarian cancer

黄海敏, 蓝秀万, 吴耀生. 肠道微生物与性激素相关疾病研究进展[J]. 生物技术通报, 2020, 36(2): 77-82.

HUANG Hai-min, LAN Xiu-wan, WU Yao-sheng. Research Progress on Intestinal Microbe and Sex Hormone Related Diseases[J]. Biotechnology Bulletin, 2020, 36(2): 77-82.

参考文献

[1] Tierney BT, Yang Z, Luber JM, et al.The landscape of genetic content in the gut and oral human microbiome[J]. Cell Host Microbe, 2019, 26(2):283-295.
[2] Lynch SV, Phimister EG, Pedersen O.The human intestinal microbiome in health and disease[J]. New England Journal of Medicine, 2016, 375(24):2369-2379.
[3] Chen B, Sun L, Zhang X.Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases[J]. J Autoimmun, 2017, 83:31-42.
[4] Petersen C, Bell R, et al. T cell-mediated regulation of the microbiota protects against obesity[J]. Science, 2019, 365(6451):eaat9351.
[5] Zhang F, et al.Response of gut microbiota in type 2 diabetes to hypoglycemic agents[J]. Endocrine, 2019, 66, 485-493.
[6] Picardo SL, Coburn B, Hansen AR.The microbiome and cancer for clinicians[J]. Crit Rev Oncol Hematol, 2019, 141:1-12.
[7] Baker JM, Al-Nakkash L, Herbst-Kralovetz MM.Estrogen-gut microbiome axis:Physiological and clinical implications[J]. Maturitas, 2017, 103:45-53.
[8] Shin JH, Park YH, Sim M, et al.Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome[J]. Res Microbiol, 2019, 170(4-5):192-201.
[9] Rizzetto L, Fava F, Tuohy KM, et al.Connecting the immune system, systemic chronic inflammation and the gut microbiome:The role of sex[J]. J Autoimmun, 2018, 92:12-34.
[10] Insenser M, Murri M, et al.Gut microbiota and the polycystic ovary syndrome:influence of sex, sex hormones, and obesity[J]. J Clin Endocrinol Metab, 2018, 103(7):2552-2562.
[11] Org E, Mehrabian M, Parks BW, et al.Sex differences and hormonal effects on gut microbiota composition in mice[J]. Gut Microbes, 2016, 7(4):313-322.
[12] Sinha T, Vich Vila A, Garmaeva S, et al.Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles[J]. Gut Microbes, 2019, 10(3):358-366.
[13] Poutahidis T, Springer A, Levkovich T, et al.Probiotic microbes sustain youthful serum testosterone levels and testicular size in aging mice[J]. PLoS One, 2014, 9(1):e84877.
[14] Markle JG, Frank DN, Mortin-Toth S, et al.Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity[J]. Science, 2013, 339(6123):1084-1088.
[15] McCartney CR, Marshall JC. Polycystic ovary syndrome[J]. N Engl J Med, 2016, 375(1):54-64.
[16] Zeng B, Lai Z, Sun L, et al.Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance(IR-PCOS):a pilot study[J]. Res Microbiol, 2019, 170(1):43-52.
[17] Kelley ST, Skarra DV, Rivera AJ, et al.The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome[J]. PLoS One, 2016, 11(1):e0146509.
[18] Guo Y, Qi Y, Yang X, et al.Association between polycystic ovary syndrome and gut microbiota[J]. PLoS One, 2016, 11(4):e0153196.
[19] Qi X, Yun C, Sun L, et al.Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome[J]. Nat Med, 2019, 25(8):1225-1233.
[20] Miyoshi M, Ogawa A, Higurashi S, et al.Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice[J]. Eur J Nutr, 2014, 53(2):599-606.
[21] Zhang J, Sun Z, Jiang S, et al.Probiotic bifidobacterium lactis V9 regulates the secretion of sex hormones in polycystic ovary syndrome patients through the gut-brain axis[J]. mSystems, 2019, 4(2).
[22] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[23] Giudice A, Barbieri A, Bimonte S, et al.Dissecting the prevention of estrogen-dependent breast carcinogenesis through Nrf2-dependent and independent mechanisms[J]. Onco Targets Ther, 2019, 12:4937-4953.
[24] Samavat H, Kurzer MS.Estrogen metabolism and breast cancer[J]. Cancer Lett, 2015, 356(2):231-243.
[25] Zhang Y, Eades G, Yao Y, et al.Estrogen receptor alpha signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2[J]. J Biol Chem, 2012, 287(49):41514-41522.
[26] Tao J, Li S, Gan RY, et al.Targeting gut microbiota with dietary components on cancer:Effects and potential mechanisms of action[J]. Crit Rev Food Sci Nutr, 2019:1-13.
[27] Fernandez MF, Reina-Perez I, Astorga JM, et al.Breast cancer and its relationship with the microbiota[J]. Int J Environ Res Public Health, 2018, 15(8):1747.
[28] Plaza-Diaz J, Alvarez-Mercado AI, Ruiz-Marin CM, et al.Association of breast and gut microbiota dysbiosis and the risk of breast cancer:a case-control clinical study[J]. BMC Cancer, 2019, 19(1):495.
[29] Luu TH, Michel C, Bard JM, et al.Intestinal proportion of Blautia sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer[J]. Nutr Cancer, 2017, 69(2):267-275.
[30] Goedert JJ, Jones G, Hua X, et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women:a population-based case-control pilot study[J]. J Natl Cancer Inst, 2015, 107(8), pii:djv147.
[31] Goedert JJ, Hua X, Bielecka A, et al.Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota[J]. Br J Cancer, 2018, 118(4):471-479.
[32] Shi J, Geng C, Sang M, et al.Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer[J]. Oncol Lett, 2019, 17(6):5050-5056.
[33] Macpherson AJ, Geuking MB, McCoy KD. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria[J]. Immunology, 2005, 115(2):153-162.
[34] Rutkowski Melanie R, Stephen Tom L, Svoronos N, et al.Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation[J]. Cancer Cell, 2015, 27(1):27-40.
[35] Lakritz JR, Poutahidis T, Mirabal S, et al.Gut bacteria require neutrophils to promote mammary tumorigenesis[J]. Oncotarget, 2015, 6(11):9387-9396.
[36] Routy B, Le Chatelier E, Derosa L, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371):91-97.
[37] Nanda R, Chow LQ, Dees EC, et al.Pembrolizumab in patients with advanced triple-negative breast cancer:Phase Ib KEYNOTE-012 study[J]. J Clin Oncol, 2016, 34(21):2460-2467.
[38] Laviolette LA, Garson K, et al.17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer[J]. Endocrinology, 2010, 151(3):929-938.
[39] Vieira-Potter VJ, Cross TL, et al.Soy-induced fecal metabolome changes in ovariectomized and intact female rats:relationship with cardiometabolic health[J]. Sci Rep, 2018, 8(1):16896.
[40] Viaud S, Saccheri F, Mignot G, et al.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science, 2013, 342(6161):971-976.
[41] Daillere R, Vetizou M, et al.Enterococcus hirae and Barnesiella in-testinihominis facilitate cyclophosphamide-induced therapeutic im-munomodulatory effects[J]. Immunity, 2016, 45(4):931-943.
[42] Gloux K, Berteau O, El Oumami H, et al.A metagenomic beta-glucuronidase uncovers a core adaptive function of the human intestinal microbiome[J]. Proc Natl Acad Sci USA, 2011, 108(S1):4539-4546.
[43] McIntosh FM, Maison N, Holtrop G, et al. Phylogenetic distribution of genes encoding beta-glucuronidase activity in human colonic bacteria and the impact of diet on faecal glycosidase activities[J]. Environ Microbiol, 2012, 14(8):1876-1887.
[44] Shen RL, Dang XY, Dong JL, et al.Effects of oat beta-glucan and barley beta-glucan on fecal characteristics, intestinal microflora, and intestinal bacterial metabolites in rats[J]. J Agric Food Chem, 2012, 60(45):11301-11308.
[45] Plottel CS, Blaser MJ.Microbiome and malignancy[J]. Cell Host Microbe, 2011, 10(4):324-335.
[46] Tremellen K, Pearce K.Dysbiosis of gut microbiota(DOGMA)-a novel theory for the development of polycystic ovarian syndrome[J]. Med Hypotheses, 2012, 79(1):104-112.
[47] Gnauck A, Lentle RG, Kruger MC.The characteristics and function of Bacterial lipopolysaccharides and their endotoxic potential in humans[J]. Int Rev Immunol, 2016, 35(3):189-218.